Compare Enveric Biosciences Inc (ENVB) vs Gap Inc (GAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Gap Inc — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Gap Inc trades at $23.33 (market cap $8.29B). The key difference: Gap Inc is far larger — about 1239.2× Enveric Biosciences Inc's market cap, and Gap Inc pays a 2.96% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Gap Inc for 37 Days on average.
| ENVB | GAP | |
|---|---|---|
Market Cap | $6.69M | $8.29B |
Volume | 41,141 | 5,470,564 |
Sector | Health | Consumer Cyclical |
52-Week High | $10.80 | $29.13 |
52-Week Low | $1.27 | $18.35 |
Typical Hold Time | 14 Days | 37 Days |
Enterprise Value | -$1.60M | $11.53B |
Dividend Yield | — | 2.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
Gap trades at $23.36, down 1.81% for the day, with a bullish technical outlook from moving averages. The company shows strong profitability with a 43.26% gross margin and 8.14% net margin, supported by recent earnings beats. Revenue has stabilized around $15B, and cash flow from operations remains robust at $1.49B. Recent news highlights brand revitalization efforts, including music partnerships and board appointments, signaling strategic moves to engage customers.
The outlook is positive given low valuations (P/E 7.11, P/S 0.58) and analyst consensus target of $25.67, implying upside. Risks include reliance on Old Navy's turnaround and competitive pressures. Institutional activity is mixed, with some funds reducing stakes while others increase positions, reflecting cautious optimism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Gap Inc
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Read more on GAP →
